Regulus Therapeutics, a biopharmaceutical company that discovers and develops new medicines targeting microRNAs, has appointed Neil Gibson, Ph.D., as its chief scientific officer. 

Gibson joins Regulus from the oncology research unit at Pfizer in California where he most recently held positions as chief scientific officer and oncology therapeutic area head. Prior to Pfizer, he held positions at OSI Pharmaceuticals including chief scientific officer. Gibson's industry experience has also included service as a director for cancer research in the department of cancer and osteoporosis for Bayer.